Revenue Growth and Profitability
Year-over-year revenue growth accelerated to 29% excluding Keystone, with record segment adjusted EBITDA performance seeing 80% growth. Medical segment adjusted EBITDA margin increased to over 15% in Q3 2025, up from 10.8% in the prior year.
Strategic Transactions and Rebranding
Completed two transformational transactions: divestiture of the passenger business and acquisition of Keystone Perfusion. Rebranded as Strata Critical Medical with a new ticker symbol, SRTA.
Positive Free Cash Flow
Generated positive free cash flow from continuing operations, with expectations to consistently generate free cash flow moving forward.
Strong Performance in New and Existing Services
Revenue from organ placement services more than doubled year-over-year, and a new organ logistics customer was added late in Q3.